MYC and cholangiocarcinoma: Thus, CLK3-mediated phosphorylation of USP13 at Tyr708 promotes cholangiocarcinoma progression by activating c-Myc-induced purine synthesis, providing a new and viable therapeutic target for the treatment of cholangiocarcinoma associated with CLK3 mutations (Zhou et al., 2020).